5.01% 0.0198

Azitra Inc (AZTR)

개요 뉴스 가격 이력 토론 예측

Azitra Inc 주식(AZTR)의 최신 뉴스

Azitra Inc (AZTR)

Azitra Inc 주식(AZTR)의 최신 뉴스

Azitra, Inc. to Present at Biotech Showcase 2025 Alongside the J.P. Morgan Annual Healthcare Conference - StreetInsider.com

Azitra to Present Growth Strategy at Biotech Showcase 2025: Clinical Pipeline & Development Plans in Focus - StockTitan

Azitra stock plunges to 52-week low, hits $0.42 - Investing.com India

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Bu - GuruFocus.com

AZTR: Planning 2nd Site for ATR-12 Trial - MSN

Azitra stock plunges to 52-week low at $0.46 amid steep decline - Investing.com Australia

500: Something went wrong - Investing.com Canada

Azitra (NYSEAMERICAN:AZTR) Shares Down 3.9% – Here’s Why - Defense World

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates - PR Newswire

Azitra to Present at BIO-Europe 2024 - BioSpace

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit - Marketscreener.com

Azitra Joins 2024 Maxim Healthcare Virtual Summit - FinancialNews.co.uk

Netherton Syndrome Treatment Industry is Expected to Reach $8 Billion by 2034 -Lifemax Laboratories, Azitra, Inc, Sixera – IndiaPolitics.com - IndiaPolitics.com

Azitra stock plunges to 52-week low, hits $0.49 By Investing.com - Investing.com South Africa

Azitra stock plunges to 52-week low, hits $0.49 - Investing.com

Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga

Azitra to present EGFR inhibitor toxicity treatment data By Investing.com - Investing.com Australia

Azitra to present EGFR inhibitor toxicity treatment data - Investing.com India

AZTRAzitra Inc Latest Stock News & Market Updates - StockTitan

Mexico's inflation undershoots forecasts ahead of rate decision - Investing.com

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress - Business Wire

AZTR’s Market Fluctuations: Is Now the Right Time to Invest? - The InvestChronicle

FDA fast tracks Azitra's new dermatology treatment - Investing.com

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors - StockTitan

Taking a Closer Look At Azitra Inc (AZTR) Following Its Recent Trade - Knox Daily

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com

Azitra (NYSEAMERICAN:AZTR) Stock Price Down 7.8% - Defense World

Azitra, Inc. (NYSEAMERICAN:AZTR) Short Interest Update - Defense World

Azitra Inc’s latest rating changes from various analysts - Knox Daily

A significant driver of top-line growth: Azitra Inc (AZTR) - SETE News

Financial Metrics Exploration: Understanding Azitra Inc (AZTR) Through Ratios - The Dwinnex

Do investors need to be concerned about Azitra Inc (AZTR)? - US Post News

Azitra doses first subject in Phase Ib Netherton syndrome treatment trial - Yahoo Finance

Azitra begins phase 1b trial for Netherton syndrome treatment - Investing.com

Views of Wall Street’s Leading Experts on Azitra Inc - SETE News

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome - Marketscreener.com

Trading Day Triumph: Azitra Inc (AZTR) Ends at 0.71, a -5.08 Surge/Plunge - The Dwinnex

Azitra Inc [AZTR] stock for 10,034 USD was bought by Staskey Norm - Knox Daily

FDA clears Azitra's Phase 1/2 trial for skin rash treatment - Investing.com

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors - Marketscreener.com

A Look at Azitra Inc (AZTR) Shares in the Recent Past Indicates Growth - SETE News

Investing in Azitra Inc (AZTR) Is Getting More Attractive - Knox Daily

Azitra Inc Inc. (AZTR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

AZTR과 유사한 종목